If you had a look at how the market has treated OCC’s SP, you’d think the company has been resting on its laurels and hadn’t obtained 5 regulatory approvals in 5 weeks. You’d think not much is happening elsewhere in the business either.
As you can here, the reality is the company and US team are working their butts off to drive commercialisation efforts quietly behind the scenes. Minghao Zheng says they’ve had “one of the most productive trips”. Visited leading universities and hospitals across the country, met with new distributors and prepared for new orders incoming (where stock has already arrived in the US distribution centre). We’re super ready!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
0.005(0.40%) |
Mkt cap ! $304.1M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.25 | $34.20K | 27.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 51541 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 726 | 2 |
View Market Depth
| Last trade - 10.00am 30/06/2025 (20 minute delay) ? |
| OCC (ASX) Chart |